학술논문
Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18–60 years: A double-blind, non-inferiority, randomized controlled trial
Document Type
Article
Author
Source
In Vaccine 2 April 2024 42(9):2254-2259
Subject
Language
ISSN
0264-410X